FY2025 · ended Dec 31, 2025 · Revenue $69.65M, -17.7% YoY · Filed Feb 26, 2026
Personalis, Inc. (PSNL) files with the SEC under industry code 8071, Services-Medical Laboratories. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $69.6 million and a net loss of $81.3 million. Free cash flow was -$79.5 million. As of Sep 30, 2026 it held $190.6 million in cash and investments and $39.5 million in total debt.
Revenue (TTM)
$80.77M
+16.9% vs year-ago TTM
Net income (TTM)
$-119.33M
-61.5% vs year-ago TTM
Operating cash flow (TTM)
$-97.57M
-61.3% vs year-ago TTM
Free cash flow (TTM)
$-107.69M
-62.7% vs year-ago TTM
EPS (TTM)
$-1.17
-33.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
104.63M
+18.5% vs prior year
Net cash
$151.12M
as of Sep 30, 2026
Operating margin
-156.7%
FY 2026
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- PSNL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Fremont, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1527753
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $69.6M | $84.6M | $73.5M | $65.0M | $85.5M |
| Operating income | -$88.1M | -$68.3M | -$109.9M | -$115.5M | -$65.4M |
| Net income | -$81.3M | -$81.3M | -$108.3M | -$113.3M | -$65.2M |
| Diluted EPS | -$0.91 | -$1.37 | -$2.25 | -$2.48 | — |
| Operating cash flow | -$74.9M | -$45.1M | -$56.3M | -$70.2M | -$70.8M |
| Free cash flow | -$79.5M | -$46.8M | -$67.2M | -$120.1M | -$81.9M |
| Total assets | $334.2M | $270.3M | $225.1M | $292.7M | $396.5M |
| Total liabilities | $73.0M | $67.3M | $95.7M | $74.6M | $86.2M |
| Stockholders' equity | $261.2M | $203.0M | $129.4M | $218.1M | $310.3M |
| Cash and investments | $240.0M | $185.0M | $114.2M | $167.7M | $287.1M |
| Total debt | $42.0M | $42.6M | $46.1M | $46.4M | $56.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Other events
|
Oct 6, 2026 | Oct 2, 2026 |
| 8-K |
Current report
Other events
|
Aug 20, 2026 | Aug 20, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
All 555 Personalis, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.